glp-1 agonist clinical trials Lilly orforglipron oral phase 3 weight loss trial Issue 42: GLP-1 RA Drug
Description
Copayments are expected to be high
Semaglutide, a type of GLP-1R agonists with 94% sequence homology to GLP-1 and with an extended half-life of approximately 1 week, has been clinically approved to treat T2DM and is available in subcutaneous and oral dosage form (136, 137)
In vitro signaling studies demonstrated that tirzepatide was able to activate the GIP receptor with comparable potency to native GIP (57)
Ouyang, Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents, Int
